- Home
- ZYBT vs ORGO Comparison
ZYBT vs ORGO Comparison
Compare ZYBT & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYBT
- ORGO
- Stock Information
- Founded
- ZYBT 2004
- ORGO 1985
- Country
- ZYBT China
- ORGO United States
- Employees
- ZYBT N/A
- ORGO N/A
- Industry
- ZYBT
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- ZYBT
- ORGO Health Care
- Exchange
- ZYBT NYSE
- ORGO Nasdaq
- Market Cap
- ZYBT 340.3M
- ORGO 384.4M
- IPO Year
- ZYBT 2025
- ORGO N/A
- Fundamental
- Price
- ZYBT $5.88
- ORGO $3.69
- Analyst Decision
- ZYBT
- ORGO Buy
- Analyst Count
- ZYBT 0
- ORGO 2
- Target Price
- ZYBT N/A
- ORGO $5.50
- AVG Volume (30 Days)
- ZYBT 449.3K
- ORGO 984.0K
- Earning Date
- ZYBT 01-01-0001
- ORGO 08-07-2025
- Dividend Yield
- ZYBT N/A
- ORGO N/A
- EPS Growth
- ZYBT N/A
- ORGO N/A
- EPS
- ZYBT 0.06
- ORGO N/A
- Revenue
- ZYBT $26,111,272.00
- ORGO $458,760,000.00
- Revenue This Year
- ZYBT N/A
- ORGO $2.62
- Revenue Next Year
- ZYBT N/A
- ORGO $12.46
- P/E Ratio
- ZYBT $108.13
- ORGO N/A
- Revenue Growth
- ZYBT N/A
- ORGO 5.35
- 52 Week Low
- ZYBT $3.50
- ORGO $2.28
- 52 Week High
- ZYBT $14.30
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- ZYBT N/A
- ORGO 58.16
- Support Level
- ZYBT N/A
- ORGO $3.13
- Resistance Level
- ZYBT N/A
- ORGO $3.69
- Average True Range (ATR)
- ZYBT 0.00
- ORGO 0.22
- MACD
- ZYBT 0.00
- ORGO 0.09
- Stochastic Oscillator
- ZYBT 0.00
- ORGO 87.01
About ZYBT ZHENGYE BIOTECHNOLOGY HLDG LTD
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.